Join Arpita Ray, principal scientist at BenevolentAI for a talk on how we apply a combination of AI models and machine learning tools and patient OMICS datasets to better predict drug targets.
Artificial Intelligence in drug discovery- Glioblastoma as a case study
Application of Artificial Intelligence (AI) has seen a significant rise in the healthcare and drug development industry over the last 5 years. At Benevolent AI (BAI), we are disrupting the traditional way of drug development by applying a combination of AI models and ML tools along with patient ‘omics datasets to a disease centric knowledge graph, to predict drug targets that could be therapeutically targeted to treat the disease. The BAI knowledge graph which integrates structured and unstructured biomedical data powers AI to generate novel insights for a particular disease or mechanism.
One of the diseases programs for application of our discovery platform / technology is Glioblastoma Multiforme, the most aggressive brain tumour with a high unmet need. Using a fleet of best-in-class algorithms along with ‘omics-based prediction models and ML models on patient data, applied to the disease biograph, we aimed to identify putative therapeutic targets that could possibly perturb survival of glioblastoma stem cells or synergise with radiation. These predictions were tested in disease relevant assays using GBM-patient derived cells in a 2D or 3D format. Preliminary data indicates identification of lesser known disease-target relationships using the Benevolent platform approach
Arpita is a principal scientist at BenevolentAI. She has over a decade ofexperience in drug discovery focussing particularly in cancer research.Arpita did her PhD from the University of Manchester on a Wellcome Trustfunded programme in Molecular and Cellular Biology. She then went on todo a Postdoc from the University of Liverpool on a grant sponsored byCancer Research UK. She has since then worked on several cancerresearch programmes at the Institute of Cancer Research (ICR) andbiotech start-ups in London. Her current focus within Benevolent is tryingto identify novel drug targets for an oncology program and aneurodegenerative disease program.